Skip to Content

Generic Ionsys Availability

Ionsys is a brand name of fentanyl, approved by the FDA in the following formulation(s):

IONSYS (fentanyl hydrochloride - system;iontophoresis, transdermal)

  • Manufacturer: THE MEDICINES CO
    Approval date: May 22, 2006
    Strength(s): EQ 40MCG BASE/ACTIVATION [RLD]

Has a generic version of Ionsys been approved?

No. There is currently no therapeutically equivalent version of Ionsys available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ionsys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Electrotransport delivery device
    Patent 5,697,896
    Issued: December 16, 1997
    Inventor(s): McNichols; Larry A. & Badzinski; John D. & Haak; Ronald P.
    Assignee(s): Alza Corporation
    An electrotransport delivery device (410) includes control circuitry for discontinuously delivering a beneficial agent (eg, a drug) through a body surface (eg, skin 400). For example, the device may be the type which is manually activated by the patient or other medical personnel to activate electrotransport drug delivery. Once electrotransport delivery has been activated, a timer (221) counts a transition interval, typically about one minute, during which the device is allowed to operate and the impedance of the body surface (400) is allowed to stabilize. Thereafter, the electrotransport current and voltage are then monitored and compared to predetermined limits. Allowing for the transition interval permits tighter tolerances in monitoring the applied current.
    Patent expiration dates:
    • December 16, 2016
      ✓ 
      Drug product
  • Display for an electrotransport delivery device
    Patent 5,843,014
    Issued: December 1, 1998
    Inventor(s): Lattin; Gary A. & Bernstein; Keith J.
    Assignee(s): ALZA Corporation
    An electrotransport delivery device (10) with a display (14) having only on and off states, and a method of operating the display (14), are provided. Preferably, the display 14 is a light (e.g., a light emitting diode) with lit and unlit states or an audible alarm (e.g., a beeper) with sounding and silent states. The device (10) counts and stores the number of events (e.g., patient initiated drug delivery or sensed patient condition) which occur over a predetermined period of time (e.g., the period of time over which the device is worn by the patient). The event count is displayed by cycling the display (14) between on and off states according to a predetermined regimen which correlates the number of on/off cycles to the number of events. The device and method permit the use of a simple and inexpensive means (e.g., an LED) to display (e.g., to a medical technician) the number of e.g., patient initiated doses delivered over a previous period of therapy.
    Patent expiration dates:
    • December 1, 2015
      ✓ 
      Drug product
  • Iontophoretic drug delivery apparatus
    Patent 6,169,920
    Issued: January 2, 2001
    Inventor(s): Haak; Ronald P. & Meyers; Robert M. & Landrau; Felix A. & Sanders; Harold F. & Kleiner; Lothar W. & Gyory; J. Richard
    Assignee(s): Alza Corporation
    An iontophoretic delivery device (10) is provided. Device (10) has an electronic circuit (32) having electronic components such as batteries (30) mounted thereon. Device (10) also includes a pair of electrode assemblies (18, 19). The electronic circuit (32) is electrically connected to the electrode assemblies (18, 19) using an electrically conductive adhesive (34). The adhesive can also be used to electrically connect two or more electronic components within circuit (32) or to connect an electronic component to the electronic circuit (32). In one practice of the invention, the electrically conductive adhesive (44) functions as an electrode and electrically connects the circuit (32) to an agent-containing reservoir (24, 25). In a further practice of the invention, the electrically conductive adhesive (93) functions as an agent reservoir and contains the agent to be iontophoretically delivered.
    Patent expiration dates:
    • January 2, 2018
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
      ✓ 
      Drug product
  • Transdermal electrotransport delivery device including a cathodic reservoir containing a compatible antimicrobial agent
    Patent 6,181,963
    Issued: January 30, 2001
    Inventor(s): Chin; Ivan W. & Murdock; Thomas O. & Cormier; Michel J. N.
    Assignee(s): Alza Corporation
    A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. The cathode includes a cathodic electrode and a cathodic reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes i) a drug or an electrolyte salt or a mixture thereof and ii) a cetylpyridinium salt in an amount sufficient to inhibit microbial growth in the aqueous medium. The polymeric material is compatible with the cetylpyridinium salt. A process is also provided wherein when electric current flows from the source of electrical power so that the drug is transdermally delivered to the patient by electrotransport from the anodic reservoir, the cetylpyridinium salt is not transdermally delivered to the patient by electrotransport from the cathodic reservoir. A process for preparing a transdermal electrotransport drug delivery device is also provided.
    Patent expiration dates:
    • November 2, 2019
      ✓ 
      Drug product
  • Electrotransport device electrode assembly having lower initial resistance
    Patent 6,195,582
    Issued: February 27, 2001
    Inventor(s): Scott; Erik R.
    Assignee(s): ALZA Corporation
    The present invention relates generally to an electrotransport device for transdermally or transmucosally delivering a beneficial agent (e.g., a drug) to the body surface of a patient or for transdermally or transmucosally sampling a body analyte. Most particularly, the present invention relates to a configured and electrochemically reactive electrode assembly having improved start-up electrical performance and improved lag time to compliant agent delivery.
    Patent expiration dates:
    • January 28, 2019
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
      ✓ 
      Drug product
  • Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
    Patent 6,881,208
    Issued: April 19, 2005
    Inventor(s): Phipps; Joseph B. & Southam; Mary & Bernstein; Keith J. & Noorduin; Henk
    The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.
    Patent expiration dates:
    • April 19, 2022
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
  • Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof
    Patent 6,975,902
    Issued: December 13, 2005
    Inventor(s): Phipps; Joseph B. & Lattin; Gary A. & McNichols; Larry A. & Badzinski; John D.
    Assignee(s): ALZA Corporation
    A reservoir and a family of reservoirs are provided which are designed to be used with a single controller to provide a wide range of therapeutic drug delivering regimens while maintaining many of the same reservoir configurations and drug formulations. A method of making a reservoir and a family of reservoirs and incorporating them into an electrotransport system is disclosed.
    Patent expiration dates:
    • April 1, 2024
      ✓ 
      Drug product
  • Two-part electrotransport device
    Patent 8,301,238
    Issued: October 30, 2012
    Inventor(s): Netzel; Zita S. & Lemke; John & Seward; David & Read; Brian W. & White; Bradley E. & Chen; Corinna X. & Hayter; Paul
    Assignee(s): Incline Therapeutics, Inc. Alza Corporation
    A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
    Patent expiration dates:
    • September 30, 2031
      ✓ 
      Drug product
  • Self-test for analgesic product
    Patent 8,428,708
    Issued: April 23, 2013
    Assignee(s): Incline Therapeutics, Inc. Alza Corporation
    Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.
    Patent expiration dates:
    • May 21, 2032
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
  • Current control for electrotransport drug delivery
    Patent 8,428,709
    Issued: April 23, 2013
    Assignee(s): Incline Therapeutics, Inc. Alza Corporation
    Devices, systems and methods for controlling the application of current and/or voltage to deliver drug from patient contacts of an electrotransport drug delivery device by indirectly controlling and/or monitoring the applied current without directly measuring from the cathode of the patient terminal. In particular, described herein are electrotransport drug delivery systems including constant current delivery systems having a feedback current and/or voltage control module that is isolated from the patient contacts (e.g., anodes and cathodes). The feedback module may be isolated by a transistor from the patient contacts; feedback current and/or voltage control measurements may be performed at the transistor rather than at the patient contact (e.g., cathode).
    Patent expiration dates:
    • June 11, 2032
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
      ✓ 
      Drug product
  • Switch validation circuit and method
    Patent 8,781,571
    Issued: July 15, 2014
    Assignee(s): Incline Therapeutics, Inc.
    A switch operated therapeutic agent delivery device is described. Embodiments of the operated therapeutic agent delivery device include a switch that can be operated by a user, a device controller connected to the switch through a switch input where the device can actuate the device when certain predetermined conditions are met, and a switch integrity subcircuit which is used to detect a fault or a precursor to a fault.
    Patent expiration dates:
    • March 31, 2032
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
      ✓ 
      Drug product
  • Self-test for analgesic product
    Patent 9,095,706
    Issued: August 4, 2015
    Assignee(s): Incline Therapeutics, Inc. Alza Corporation
    Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.
    Patent expiration dates:
    • February 3, 2033
      ✓ 
      Drug product
  • Method of storing an electrotransport drug delivery device
    Patent 9,364,656
    Issued: June 14, 2016
    Assignee(s): Incline Therapeutics, Inc. Alza Corporation
    A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
    Patent expiration dates:
    • September 30, 2031
      ✓ 
      Patent use: METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide